New bagel shop to open in former Absolute Bagels location on Upper West Side
UPPER WEST SIDE, Manhattan (PIX11) — A new bagel shop on Manhattan's Upper West Side is in the works. It's set to replace an iconic business that had been there for nearly 40 years.
A steady stream of Upper West Siders walked past the new signage outside the former location for Absolute Bagels with curiosity on Wednesday. Many neighbors say the closure in December left a hole in the community.
More Local News
'Best bagel in New York City,' said Upper West Side resident Mark Fleischman.
Upper West Side resident Abraham Alvarez said, 'The taste, it had a bit of sweetness, some sourness. A little expensive, but a good size. They were good.'
A place so beloved, many customers said they were willing to overlook the slew of health violations the business received from the city before it closed.
More: Latest News from Around the Tri-State
When asked if he was OK with the violations, Alvarez said, 'I did want them to [stay open]. I would check my bagel for bugs.'
Fleischman said, 'The health violations were pretty grim, but I was totally fine with it. If they'd kept on making bagels, I would have totally been OK with it.'
That's why many people are happy to hear a new bagel shop is opening. But there's a catch. The original business is not back.
Rafe Evans is with Walker, Malloy & Company, the broker for the building. Last week, he signed a new lease for the commercial space with new tenants.
Evans said the new business owners are a group that already owns a few bagel shops in New York and New Jersey.
'They are going to rebuild it from scratch. They need everything. Floors, walls, ceilings, the works,' Evans said. 'We were surprised to see they're calling themselves the new Absolute Bagels. We do get why they're doing that.'
Evans said the new owners have no connection to the family that owned the previous business for 36 years. He doesn't believe the recipes will be similar either.
'Sam, the former owner, was asked if he wanted to sell his recipes, and he said anyone can make a bagel,' Evans said.
Regardless, locals said they are excited that there is new life coming to the area.
'The cyclical nature of economic opportunity in New York is pretty much a staple. There's always something opening and closing. When one thing closes, another opens,' one man said.
Fleischman said, 'We'll see. If it's anything like Absolute, they'll have my business.'
PIX11 News reached out to the new owners of the bagel shop. The group did not want to comment right now, but we're told renovations should take several months.
PIX11 also reached out to the original owners of Absolute Bagels but has yet to hear back.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split
CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share (the 'Common Stock'), at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company's Common Stock is expected to begin trading on a split-adjusted basis when the market opens on June 12, 2025, under the existing trading symbol 'ERNA.' The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The new CUSIP number following the reverse stock split will be 114082 308. As a result of the reverse stock split, every 15 shares of the Company's Common Stock issued and outstanding will be automatically reclassified into one new share of Common Stock. The reverse stock split will not modify any rights or preferences of the shares of the Company's Common Stock. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company's outstanding equity awards, as applicable, and warrants, as well as to the number of shares issued and issuable under the Company's equity incentive plans. The Common Stock issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split will not affect the number of authorized shares of Common Stock or the par value of the Common Stock. The reverse stock split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on June 2, 2025 at a ratio in the range of 1-for-10 to 1-for-15, such ratio to be determined by the Board of Directors. The Company's Board of Directors approved the reverse stock split at the ratio of 1-for-15. No fractional shares will be issued in connection with the reverse stock split, and no cash or other consideration will be paid in connection with any fractional shares. Stockholders who otherwise would have held a fractional share after giving effect to the reverse stock split will instead own one whole share of the post-reverse stock split Common Stock. As of the date of this press release, the Company had 110,418,022 shares of Common Stock issued and outstanding, which it anticipates will result in approximately 7,361,201 shares of Common Stock issued and outstanding on a split-adjusted basis, without giving effect to any rounding for fractional shares. Computershare Inc. and its affiliate Computershare Trust Company, N.A., the Company's transfer agent (collectively, 'Computershare'), will act as the exchange agent for the reverse stock split. Stockholders of record holding certificates representing pre-split shares of the Company's Common Stock will receive a letter of transmittal from Computershare with instructions on how to surrender certificates representing pre-split shares. Stockholders should not send in their pre-split certificates until they receive a letter of transmittal from Computershare. Stockholders with book-entry shares or who hold their shares through a bank, broker, or other nominee will not need to take any action. Stockholders of record who held pre-split certificates will receive their post-split shares in book-entry form and will receive a statement from Computershare regarding their Common Stock ownership post-reverse stock split. Additional information about the reverse stock split can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission (the 'SEC') on April 14, 2025, which is available at and on the Company's website at Alongside Ernexa's recent financings and corporate restructuring, the Company believes this reverse stock split is a key step in strengthening its financial foundation and maintaining access to the capital markets needed to advance its clinical programs. About Ernexa Therapeutics Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative stem cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexa's core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa's allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment, without needing patient-specific cell harvesting. ERNA-101 is the company's lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-102 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company's initial focus is to develop ERNA-101 for the treatment of ovarian cancer. For more information, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to the impact of the reverse stock split. Forward-looking statements are based upon Ernexa's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law. Media & Investor Relations Contact investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
GrowGeneration Announces International Expansion with Distribution Agreement Across the European Union and Footprint in Costa Rica
DENVER, June 10, 2025 (GLOBE NEWSWIRE) -- GrowGeneration Corp. (NASDAQ: GRWG) ('GrowGen' or the 'Company'), the nation's largest specialty retailer of hydroponic and organic gardening products, today announced it has entered into a distribution agreement with V1 Solutions, a Macedonia-based company that will act as GrowGen's sales and marketing partner for its proprietary product lines throughout the European Union. Additionally, the Company announced the distribution of its proprietary products in Costa Rica, making its products available to cultivators in Central America. Targeted EU Expansion Driven by Evolving Cannabis LandscapeV1 Solutions has developed and maintains key strategic relationships with commercial cultivators across the European region. This agreement enables GrowGen to meet the growing demand for advanced cultivation products that comply with evolving regulatory and quality standards as cannabis reform accelerates across the European Union. Target markets include: Germany, where recreational cannabis was legalized in 2024, unlocking significant commercial and medical cultivation potential. Portugal, a leading exporter of medical cannabis to the EU and a hub for EU-GMP-certified cultivation. Malta and Luxembourg, which have enacted progressive cannabis reform and are scaling their domestic cultivation industries. The Netherlands, launching pilot adult-use programs with government-licensed growers. Czech Republic and Greece, where updated regulatory frameworks are attracting major cultivation investments. Macedonia, as a strategic Balkan hub supporting EU-facing cannabis production. Uruguay, a pioneer in cannabis legalization, opening doors for broader South American market expansion. GrowGeneration will supply commercial cultivators, garden centers, and licensed operators in these countries with its proprietary brands—Drip Hydro, Char Coir, Ion Lighting, Power Si, and The Harvest Company—designed by growers for growers. Costa Rica: Gateway to Central American ExpansionGrowGen has also launched its proprietary brands in Costa Rica, whose government has issued over 50 licenses for hemp and cannabis production during the past year. The country's favorable growing conditions and developing export infrastructure make it a key growth market in Central America. 'As legalization advances, the EU and Costa Rica are rapidly becoming some of the most promising cannabis cultivation markets in the world,' said Darren Lampert, GrowGen's Co-Founder and Chief Executive Officer. 'We are thrilled to bring our proven product lines to professional growers across Europe and Central America, who are seeking yield-maximizing, cost-effective solutions backed by North American cultivation expertise.' International Expansion StrategyGrowGen is actively exploring additional markets in Eastern Europe and Latin America, consistent with its strategy to serve high-growth regions through local partnerships and product education. GrowGeneration's international expansion activities align with its. The Company's international sales infrastructure, regulatory expertise, and strong distribution network position it to capitalize on the cannabis cultivation boom in regions where legalization continues to advance. About GrowGeneration Corp:GrowGen is the nation's largest specialty hydroponic and organic gardening retailer. GrowGen carries and sells thousands of products, such as nutrients, additives, growing media, lighting, environmental control systems, and benching and racking, including proprietary brands such as Charcoir, Drip Hydro, Power Si, Ion lights, The Harvest Company, and more. The Company also operates an online superstore for cultivators at as well as a wholesale business for resellers, and a benching, racking, and storage solutions business, Mobile Media or MMI. To be added to the GrowGeneration email distribution list, please email GrowGen@ with GRWG in the subject line. Forward Looking Statements:This press release may include predictions, estimates or other information that might be considered forward-looking within the meaning of applicable securities laws. While these forward-looking statements represent current judgments, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect opinions only as of the date of this release. Please keep in mind that the Company does not have an obligation to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. When used herein, words such as 'look forward,' 'expect,' 'believe,' 'anticipate,' 'estimate,' or variations of such words and similar expressions are intended to identify forward-looking statements. Factors that could cause actual results to differ materially from those contemplated in any forward-looking statements made by us herein are often discussed in filings made with the United States Securities and Exchange Commission, available at: and on the Company's website, at: Contacts:KCSA Strategic CommunicationsPhilip CarlsonManaging DirectorT: 212-896-1233E: GrowGen@
Business Wire
an hour ago
- Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Treace Medical
NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Treace Medical Concepts, Inc. ('Treace' or the 'Company') (NASDAQ: TMCI) and reminds investors of the June 10, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System (the 'Lapiplasty'); (2) as a result, Treace Medical's revenue declined and the Company needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function); and (3) Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. On May 7, 2024, after market hours, when the Company issued a press release reporting, among other things, that it lowered its full-year 2024 revenue guidance from between $220 million and $225 million to between $201 million and $211 million. During the associated earnings call the same day, Defendants revealed competition from minimally invasive osteotomy and Lapiplasty 'knockoffs' created headwinds for Lapiplasty growth. On this news, the Company's stock price fell $6.95, or nearly 63%, to close at $4.17 per share on May 8, 2024, on unusually high trading volume. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Treace's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Treace class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
